Skip to main content

Table 1 Clinicopathological features of the patients with locally advanced NSCLC

From: Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Characteristics Number of cases (%)
Age 60 ± 9.31
 > 60 14 (50.00)
  ≤ 60 14 (50.00)
Gender  
 Male 24 (85.71)
 Female 4 (14.29)
Stage  
 IIIA 13 (46.43)
 IIIB 15 (53.57)
Pathological type  
 Adenocarcinoma 11 (39.29)
 Squamous cell carcinoma 17 (60.71)
Short-term outcome (RECIST)  
 Complete response 1 (3.57)
 Partial response 14 (50.00)
 Stable disease 8 (28.57)
 Progressive disease 5 (17.86)
PFS 17 (range 7.89 ~ 26.12) months
OS 36 (range 11.24 ~ 60.76) months
 1 year survival rate 25 (89.29)
 3 years survival rate 15 (53.57)
 5 years survival rate 6 (21.43)